Anticardiolipin IgG antibodies are autoantibodies that target cardiolipin, a negatively charged phospholipid found primarily in the inner mitochondrial membrane and human plasma lipoproteins.
These antibodies also bind to other negatively charged phospholipids like phosphatidylserine and phosphatidylinositol.
The presence of anticardiolipin IgG antibodies is associated with various clinical complications, including arterial and venous thrombosis, recurrent pregnancy loss, and thrombocytopenia.
IgG is often the most clinically relevant isotype of anti-cardiolipin antibodies, and therefore are significant in diagnosing antiphospholipid syndrome (APS).
New ELISA tests using beta2-glycoprotein 1 as an antigen have improved the specificity of detecting these antibodies, aiding in the more reliable diagnosis of APS.
Cardiolipin is a phospholipid component found primarily in the inner mitochondrial membrane of cells, where it is important in maintaining mitochondrial function and energy production.
It interacts with respiratory chain complexes and substrate carrier proteins, contributing to the formation of respiratory supercomplexes.
Cardiolipin (CL) is a unique phospholipid found exclusively in mitochondrial membranes of mammalian cells, so it is particularly abundant in tissue that is rich in mitochondria including the heart, skeletal muscle, and liver tissues [8., 10.].
Cardiolipin is a negatively charged phospholipid, which helps it maintain the structure of the inner mitochondrial membrane and the charge which is essential for proper functioning of the electron transport chain.
Cardiolipin is also found in normal human plasma lipoproteins including very low-density lipoproteins (VLDL), low-density lipoproteins (LDL), and high-density lipoproteins (HDL). The majority of CL (67%) is in LDL [4.].
Energy Production in Cells
Maintaining Mitochondrial Structure
Role in Cell Death
Protein Interaction
Anti-cardiolipin (anti-CL) antibodies are autoantibodies targeting cardiolipin, a negatively charged phospholipid.
These antibodies also bind to other negatively charged phospholipids such as phosphatidylserine and phosphatidylinositol but not to phospholipids that contain a positive charge like phosphatidylcholine.
This suggests anti-CL antibodies are specific to negatively charged phospholipids in general.
Anti-cardiolipin IgG antibodies are antibodies of the IgG subclass that target cardiolipin and other negatively charged phospholipids.
Anti-cardiolipin antibodies are primarily associated with the immune system's attack on negatively charged phospholipids, potentially leading to various clinical complications.
Changes in cardiolipin content, acyl chain composition, or peroxidation are linked to mitochondrial dysfunction across various diseases including ischemia, hypothyroidism, neurodegenerative diseases, aging, and heart failure [3.].
As a manifestation of Anti-Phospholipid Thrombosis Syndrome, anti-cardiolipin antibodies are also clinically correlated with thrombosis, recurrent fetal loss, and thrombocytopenia [6.].
The presence of these antibodies, particularly IgG, is prevalent in patients with conditions like thrombosis, fetal loss, and thrombocytopenia, although no single isotype was directly linked to specific clinical outcomes [6.].
IgG antibodies are considered the most clinically relevant anti-cardiolipin antibodies in the diagnosis of Anti-Phospholipid Thrombosis Syndrome [6.].
APS includes several subgroups of antiphospholipid antibodies, such as lupus anticoagulant (LA) and anti-cardiolipin antibodies, as well as antibodies against β2-glycoprotein I (β2-GP-I), phosphatidylserine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylinositol, phosphatidylcholine, and anti-annexin-V.
APS is the most common acquired blood protein defect associated with venous and arterial thrombosis.
APS can occur independently, it is frequently associated with SLE [15.].
Clinical manifestations include:
The antiphospholipid syndrome consists of closely related but distinct clinical syndromes:
Antiphospholipid antibodies are diverse, with a subset linked to arterial and venous thrombosis and recurrent pregnancy loss
These antibodies are best diagnosed using the lupus anticoagulant test and solid-phase anticardiolipin tests, which employ enzyme-linked immunosorbent assays (ELISA) using cardiolipin or other negatively charged phospholipids as antigens.
Patients with anti-cardiolipin antibodies often have a persistent, high-level IgG isotype.
However, the anti-cardiolipin ELISA test, which uses cardiolipin on plastic plates, is very sensitive but not very specific because it can give positive results for other infections like syphilis and HIV, or autoimmune diseases besides anti-phospholipid syndrome.
To improve specificity, new ELISA tests using different antigens, such as beta2-glycoprotein 1 on oxidized plates or a mix of phospholipids, have been developed.
Testing for the presence of anti-cardiolipin antibodies requires a blood draw. While special preparation is often not required, it is important to consult with the ordering provider to confirm this.
The presence of anti-cardiolipin antibodies signals an autoimmune process, where the body mistakenly attacks its own cells or structures, which can have massive clinical consequences.
Optimal levels of anti-cardiolipin antibodies are considered undetectable, or very low.
Anticardiolipin antibodies, particularly moderate to high titer IgG, are strongly linked to arterial and venous thrombosis as well as recurrent pregnancy loss. IgM and IgA isotypes are also associated with venous thrombosis [1.].
The distribution of anticardiolipin antibody subtypes in patients with thrombosis has been shown to be: [2.]
Elevated anti-cardiolipin antibodies have also been associated with ischemia, hypothyroidism, neurodegenerative diseases, aging, and heart failure [3.].
In addition to Anti-Cardiolipin IgG, several other biomarkers are often tested to provide a comprehensive assessment of antiphospholipid syndrome (APS) and related autoimmune disorders.
Anti-β2-Glycoprotein I (aβ2GPI) antibodies are crucial in the diagnosis of APS. These antibodies target β2-glycoprotein I, a plasma protein that binds to negatively charged phospholipids [16.].
While the anticardiolipin and lupus anticoagulant tests are commonly used to detect these antibodies, the anticardiolipin ELISA lacks specificity because it can show positive results for other infections and autoimmune diseases [7.].
To improve accuracy, new ELISA tests using beta2-glycoprotein 1 as an antigen have been developed. These tests are more specific for anti-phospholipid antibodies and are more reliable for diagnosing APS [7.].
Lupus anticoagulant (LA) is a key biomarker in diagnosing antiphospholipid syndrome (APS) alongside anti-cardiolipin and anti-β2GPI antibodies [9., 12.].
Despite its name, LA is associated with thrombosis risk rather than bleeding [11.].
Dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (aPTT) are also widely recommended as confirmatory tests [9., 12.].
However, LA testing faces challenges such as poor standardization, result interpretation difficulties, and interference from anticoagulant drugs, particularly direct oral anticoagulants (DOACs) and vitamin K antagonists [5., 11.].
Click here to compare testing options and order tests for anti-cardiolipin antibodies.
[1.] Anticardiolipin Antibodies | Labcorp. Labcorp. Published 2024. Accessed August 6, 2024. https://www.labcorp.com/resource/anticardiolipin-antibodies
[2.] Bick RL. Antiphospholipid thrombosis syndromes. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2001;7(4):241-258. doi:https://doi.org/10.1177/107602960100700401
[3.] Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and disease. American Journal of Physiology-Cell Physiology. 2007;292(1):C33-C44. doi:https://doi.org/10.1152/ajpcell.00243.2006
[4.] Deguchi H, Fernández JA, Hackeng TM, Banka CL, Griffin JH. Cardiolipin is a normal component of human plasma lipoproteins. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(4):1743-1748. doi:https://doi.org/10.1073/pnas.97.4.1743
[5.] Favaloro EJ, Pasalic L, Selby R. Testing for the Lupus Anticoagulant (LA): the good, the bad, and the ugly. Research and Practice in Thrombosis and Haemostasis. Published online March 1, 2024:102385-102385. doi:https://doi.org/10.1016/j.rpth.2024.102385
[6.] Gharavi AE, Harris EN, Ra A, Hughes V. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Annals of the Rheumatic Diseases. 1987;46(1):1-6. doi:https://doi.org/10.1136/ard.46.1.1
[7.] Harris EN. Serological detection of antiphospholipid antibodies. Stroke. 1992 Feb;23(2 Suppl):I3-6. PMID: 1561672.
[8.] Hatch GM. Cardiolipin: biosynthesis, remodeling and trafficking in the heart and mammalian cells (Review). International Journal of Molecular Medicine. Published online January 1, 1998. doi:https://doi.org/10.3892/ijmm.1.1.33
[9.] Kumano O, Peyrafitte M, Amiral J. Update on laboratory practice for the diagnosis of lupus anticoagulant and the antiphospholipid syndrome. Exploration of Immunology. 2023;3(5):416-432. doi:https://doi.org/10.37349/ei.2023.00110
[10.] Lu B, Xu FY, Jiang Y, et al. Cloning and characterization of a cDNA encoding human cardiolipin synthase (hCLS1). Journal of Lipid Research. 2006;47(6):1140-1145. doi:https://doi.org/10.1194/jlr.c600004-jlr200
[11.] Molinari AC, Martini T, Banov L, et al. Lupus Anticoagulant Detection under the Magnifying Glass. Journal of Clinical Medicine. 2023;12(20):6654-6654. doi:https://doi.org/10.3390/jcm12206654
[12.] Moore GW. Testing for Lupus Anticoagulants. 2022;48(06):643-660. doi:https://doi.org/10.1055/s-0042-1744363
[13.] Paradies G, Paradies V, De Benedictis V, Ruggiero FM, Petrosillo G. Functional role of cardiolipin in mitochondrial bioenergetics. Biochimica et Biophysica Acta (BBA) - Bioenergetics. 2014;1837(4):408-417. doi:https://doi.org/10.1016/j.bbabio.2013.10.006
[14.] Pons-Estel GJ, Andreoli L, Scanzi F, Cervera R, Tincani A. The antiphospholipid syndrome in patients with systemic lupus erythematosus. Journal of Autoimmunity. 2017;76:10-20. doi:https://doi.org/10.1016/j.jaut.2016.10.004
[15.] Tincani A, Andreoli L, Chighizola C, et al. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity. 2009;42(4):257-259. doi:https://doi.org/10.1080/08916930902827918
[16.] Willis R, Papalardo E, E. Nigel Harris. Solid Phase Immunoassay for the Detection of Anti-β2 Glycoprotein I Antibodies. Methods in molecular biology. Published online January 1, 2017:201-215. doi:https://doi.org/10.1007/978-1-4939-7196-1_17